Actively Recruiting
Evaluating Intravesical T3011 Injection for High-Risk and Chemotherapy-Unresponsive Non-Muscle-Invasive Bladder Cancer
Led by ImmVira Pharma Co. Ltd · Updated on 2026-08-18
160
Participants Needed
9
Research Sites
21 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the efficacy and safety of an investigational treatment called T3011 in people with non-muscle invasive bladder cancer NMIBC that has not responded to standard therapies like BCG or chemotherapy. This Phase II study focuses on patients with high-risk or intermediatehigh-risk NMIBC who have limited treatment options after previous therapies have failed. Participants receive T3011 as an injection into the bladder once a week for six weeks during an induction phase. After a rest period, a 3-month evaluation determines if further treatment is needed. Those with no recurrence or complete response enter a maintenance phase where T3011 is given every three weeks for up to about 24 months. The study includes different cohorts based on cancer characteristics and prior treatments. Throughout the study, participants undergo regular cystoscopy, urine cytology, and imaging as needed every three months to monitor disease status. Researchers will track response rates, recurrence-free survival, and any treatment-related adverse events for up to 24 months. Participants are expected to comply with study procedures and follow-up assessments during this time.
CONDITIONS
Brief Title
A Study of T3011 in Patients With BCG-Unresponsive NMIBC or BCG-Exposed, Chemotherapy-Unresponsive NMIBC
Research Team
J
Jasmine Yang
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here